Samantha McLemore’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$61.3M Sell
283,697
-96,044
-25% -$18.4M 2.01% 22
2026
Q1
$69.6M Sell
379,741
-196,611
-34% -$36.2M 2.55% 17
2025
Q4
$101M Buy
576,352
+179,703
+45% +$29.4M 3.92% 9
2025
Q3
$55.6M Buy
396,649
+76,183
+24% +$10.3M 2.22% 22
2025
Q2
$40.2M Sell
320,466
-135,139
-30% -$16.8M 1.82% 27
2025
Q1
$62.3M Buy
455,605
+41,645
+10% +$5.95M 3.21% 15
2024
Q4
$63.3M Buy
413,960
+158,018
+62% +$26.7M 2.92% 17
2024
Q3
$49.6M Sell
255,942
-1,327
-0.5% -$278K 2.44% 20
2024
Q2
$59.6M Buy
257,269
+39,382
+18% +$8.56M 3.17% 13
2024
Q1
$47M Buy
+217,887
New +$51M 2.29% 21

Other funds holding BIIB

Samantha McLemore's BIIB Position: Q2 2026 in Review

Samantha McLemore reduced its Biogen (BIIB) stake by 25% in Q2 2026, selling an estimated $18.4M and leaving 283,697 shares worth $61.3M. The position accounts for 2.01% of the portfolio, ranked #22.

Samantha McLemore first reported a position in BIIB in Q1 2024 and has held it in 10 quarters since. The position peaked at $101M in Q4 2025. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Samantha McLemore held 283,697 shares of Biogen worth $61.3M as of Q2 2026.
  • Samantha McLemore sold 96,044 Biogen shares in Q2 2026, an estimated $18.4M.
  • Biogen made up 2.01% of Samantha McLemore's portfolio in Q2 2026, its #22 holding.
  • Samantha McLemore first reported a position in Biogen in Q1 2024 and has held it in 10 quarters since.
  • Samantha McLemore's Biogen position peaked at $101M in Q4 2025.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Patient Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.